Results 11 to 20 of about 710,958 (307)
Drugs in Context, 2022 The therapeutic approach to patients affected by advanced non-small-cell lung cancer (NSCLC) is facing rapid and continuous evolution. In recent years, the emergence of new treatment strategies, such as immunotherapy and tyrosine kinase inhibitors, has ...
Andrea De Giglio +5 more
doaj +1 more source
Targeting DNA methyltransferases in non-small-cell lung cancer [PDF]
, 2021 Despite the advances in treatment using chemotherapy or targeted therapies, due to static survival rates, non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths worldwide.
Wilson, C. +3 more
core +1 more source
Therapeutic vaccines in non-small cell lung cancer
ImmunoTargets and Therapy, 2013 Francisco Socola,1 Naomi Scherfenberg,2 Luis E Raez3 1Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Leonard M Miller School of Medicine, Miami, Florida, USA; 2University of Miami Leonard M Miller School of ...
Socola F, Scherfenberg N, Raez LE
doaj +1 more source
Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: Two case reports [PDF]
, 2008 Background: With the current improvements in primary lung care, the long-term control of brain metastases becomes a clinical challenge. No established therapeutic approaches exist for cranial relapse after response to previous radiotherapy and systemic ...
Pawel, Joachim +3 more
core +1 more source
Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer
Chinese Journal of Lung Cancer, 2021 Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T ...
Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy +1 more
doaj +1 more source
Preoperative CYFRA 21-1 and CEA as Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer [PDF]
, 2008 Objective: To validate the prognostic value of preoperative levels of CYFRA 21-1, CEA and the corresponding tumor marker index (TMI) in patients with stage I non-small cell lung cancer (NSCLC). Methods: Two hundred forty stage I NSCLC patients (80 in pT1
Hatz, Rudolf +7 more
core +1 more source
MicroRNA-24 in Cancer: A Double Side Medal With Opposite Properties
Frontiers in Oncology, 2020 MicroRNA-24 (miR-24) has been widely studied in a variety of human cancers, which plays different roles in specific type of cancers. In the present review, we summarized the recent surveys regarding the role of miR-24 in different human cancers.
Sumei Wang +18 more
doaj +1 more source
Non-small-cell lung cancer: how to manage RET-positive disease
Drugs in Context, 2022 Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signalling ...
Elisa Andrini +6 more
doaj +1 more source
Non-small-cell lung cancer: how to manage EGFR-mutated disease
Drugs in Context, 2022 The treatment of non-small-cell lung cancer (NSCLC) harbouring EGFR mutations has witnessed some major breakthroughs in the last years. On the one hand, the recent advent of the third-generation tyrosine kinase inhibitor (TKI) osimertinib has reshaped ...
Federica Pecci +6 more
doaj +1 more source
CEA, CYFRA 21-1, NSE, and ProGRP in the diagnosis of lung cancer: a multivariate approach [PDF]
, 2008 We retrospectively studied the single and combined diagnostic value of carcinoembryonic antigen (CEA), cytokeratin fragment 19 (CYFRA 21-1), neuron specific enolase (NSE) and pro-gastrin-releasing peptide (ProGRP), which were routinely analysed in ...
Gruber, Christine +4 more
core +1 more source